Figure 6.

Rosuvastatin decreases HIF-1α levels in HCC livers. Representative image of western blot analysis of HIF-1α in normal livers (N), untreated HCC (n = 4), and in rosuvastatin-treated HCC livers (n = 4) at 16 weeks. The results were normalised to the β-actin levels and expressed as a percentage of HIF-1α levels in normal livers. Data are mean ± SEM. HIF-1α was significantly increased in HCC livers compared with normal livers, ***P < .001. Rosuvastatin decreased significantly HIF-1α levels in HCC livers, **P < .01.